# Biofrontera Inc (BFRI) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/BFRI
## Company Profile
- Ticker: BFRI
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
## Stock Data
- Close: 1.25 USD
- Market cap: 13187444.32 USD
- Last updated: 2026-08-06
## Business Overview
### Dermatology Photodynamic Therapy
Biofrontera commercializes photodynamic therapy products for dermatologic disease in the United States. Its principal platform combines Ameluz, a topical photosensitizer, with the RhodoLED illumination system.
### Actinic Keratosis Franchise
Ameluz is established in actinic keratosis and is being developed for broader treatment fields and additional body locations. The company is also pursuing superficial basal cell carcinoma and acne to expand the platform.
### U.S. Commercial Infrastructure
Biofrontera operates a specialist dermatology sales organization and has restructured its economics with Biofrontera AG to retain a larger share of product value.
## Why The Stock Is Moving

The latest company update was “Biofrontera Inc. to Report Second Quarter 2026 Financial Results on August 13, 2026”. BFRI changed 0.81% and closed at $1.25 on Aug 6, 2026, indicating a relatively limited closing-price reaction to this earnings update.

## Future Catalysts

- The FDA assigned September 28, 2026, as the PDUFA action date for the Ameluz supplemental NDA in superficial basal cell carcinoma.
- Phase 3 results in actinic keratoses on the extremities, neck, and trunk are expected to support a future label-expansion filing.

## Recent News
- 2026-08-05 20:15 EST — [Biofrontera Inc. to Report Second Quarter 2026 Financial Results on August 13, 2026](https://biopharmsignal.com/news/BFRI/biofrontera-inc-to-report-second-quarter-2026-financial-results-on-august-13-202-51ded09a) — Source: Biofrontera Inc
- 2026-05-21 13:15 EST — [Biofrontera Inc. to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026](https://biopharmsignal.com/news/BFRI/biofrontera-inc-to-participate-in-the-lytham-partners-spring-2026-investor-confe-5a188e40) — Source: Biofrontera Inc
- 2026-05-14 11:30 EST — [Biofrontera Inc. Reports First Quarter 2026 Financial Results and Provides a Business Update](https://biopharmsignal.com/news/BFRI/biofrontera-inc-reports-first-quarter-2026-financial-results-and-provides-a-busi-fcdfd44e) — Source: Biofrontera Inc
- 2026-05-13 13:00 EST — [Biofrontera Launches Second Annual “Hats On” Campaign to Raise Awareness of Actinic Keratosis](https://biopharmsignal.com/news/BFRI/biofrontera-launches-second-annual-hats-on-campaign-to-raise-awareness-of-actini-d33f19a2) — Source: Biofrontera Inc
- 2026-05-08 20:00 EST — [Biofrontera Inc. to Report First Quarter 2026 Financial Results and Host a Conference Call on May 14, 2026](https://biopharmsignal.com/news/BFRI/biofrontera-inc-to-report-first-quarter-2026-financial-results-and-host-a-confer-c92fce36) — Source: Biofrontera Inc